Clinical Trial

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-21; most recent amendment 2026-01-16.
Status change: Recruiting → Active, Not Recruiting 2026-01-16
Status change: Not Yet Recruiting → Recruiting 2023-05-20
Trial Details
NCT Number NCT05740943
Lead Sponsor Guangdong Provincial People's Hospital
Collaborators: Guangzhou No.12 People's Hospital, Peking Union Medical College Hospital, Second Xiangya Hospital of Central South University
Conditions Stage III NSCLC, Surgery
Enrollment 48 participants
Start Date 2023-03-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-20